Product Name
SPG11, siRNA
Full Product Name
SPG11 siRNA (Human)
Product Synonym Names
KIAA1840; Spatacsin; Colorectal carcinoma-associated protein; Spastic paraplegia 11 protein
Product Gene Name
SPG11 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q96JI7
Specificity
SPG11 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SPG11 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SPG11 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SPG11 sirna
siRNA to inhibit SPG11 expression using RNA interference
Applications Tested/Suitable for SPG11 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SPG11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001153699.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001160227.1
[Other Products]
UniProt Primary Accession #
Q96JI7
[Other Products]
UniProt Secondary Accession #
Q4VC11; Q58G86; Q69YG6; Q6NW01; Q8N270; Q8TBU9; Q9H734; A8KAX9; B9EK60; F5H3N6[Other Products]
UniProt Related Accession #
Q96JI7[Other Products]
Molecular Weight
266,643 Da
NCBI Official Full Name
spatacsin isoform 2
NCBI Official Synonym Full Names
spastic paraplegia 11 (autosomal recessive)
NCBI Official Symbol
SPG11??[Similar Products]
NCBI Official Synonym Symbols
KIAA1840
??[Similar Products]
NCBI Protein Information
spatacsin
UniProt Protein Name
Spatacsin
UniProt Synonym Protein Names
Colorectal carcinoma-associated protein; Spastic paraplegia 11 protein
UniProt Gene Name
SPG11??[Similar Products]
UniProt Synonym Gene Names
KIAA1840??[Similar Products]
UniProt Entry Name
SPTCS_HUMAN
NCBI Summary for SPG11
The protein encoded by this gene is a potential transmembrane protein that is phosphorylated upon DNA damage. Defects in this gene are a cause of spastic paraplegia type 11 (SPG11). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]
UniProt Comments for SPG11
SPG11: Defects in SPG11 are the cause of spastic paraplegia autosomal recessive type 11 (SPG11). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, multi-pass; Membrane protein, integral
Chromosomal Location of Human Ortholog: 15q14
Cellular Component: lysosomal membrane; cytoplasm; integral to membrane; plasma membrane; nucleolus; cytoplasmic vesicle; cytosol
Molecular Function: protein binding
Disease: Spastic Paraplegia 11, Autosomal Recessive
Research Articles on SPG11
1. spastizin and spatacsin were essential components for the initiation of lysosomal tubulation. Together, these results link dysfunction of the autophagy/lysosomal biogenesis machinery to neurodegeneration.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
